TMD Titan Medical

Titan Medical Announces Achievement of all Second Quarter 2018 SPORT Surgical System Development Milestones

Titan Medical Announces Achievement of all Second Quarter 2018 SPORT Surgical System Development Milestones

TORONTO, July 09, 2018 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (NASDAQ:TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in single-port minimally invasive surgery (“MIS”), announces the achievement of all second quarter 2018 development milestones for its SPORT Surgical System.  

The Company previously provided expectations for incremental milestones as it develops its single-port robotic surgery system.  Key achievements during the second quarter included:

  • Creation of prototypes of improved workstation controls
  • Testing of the prototypes and the procurement of confirmatory feedback from surgeons
  • Completion of software and hardware change requirements
  • Finalization of computer and software architecture for production systems
  • Demonstration of satisfactory performance of lens wash system and revised instruments

“We are proud of the considerable recent progress we have made in the development and refinement of our single-port robotic surgery system.  Based on insights gained from previously completed feasibility studies, we have completed key advancements on the SPORT system to ensure that upon launch we will have an efficacious surgical system and a commercially competitive product that addresses surgeon concerns and fulfills their wish lists,” said David McNally, Titan’s chief executive officer.  “We have met all of our first and second quarter 2018 expectations. Our team is now focused on meeting all milestones for the rest of the year, with more than 80 contract engineers developing advanced software and hardware while continuing to strengthen our IP position.”

Mr. McNally continued, “The engineering of the instruments has accelerated, and the results of recent laboratory demonstrations of design revisions are encouraging.  At our Annual General Meeting on June 14th, we showcased videos of the lens wash system and an earlier generation of instruments in use during recent preclinical studies.  Maintaining a clear high-definition field of view is vital for the practical conduct of surgery.  We have posted to our website a video of the entire meeting.”

The video of management presentations of the Annual General Meeting can be found at

.

About Titan

Titan Medical Inc. is focused on research and development through to the planned commercialization of computer-assisted robotic surgical technologies for application in minimally invasive surgery. The Company is developing the SPORT Surgical System, a single-port robotic surgical system. The SPORT Surgical System is comprised of a surgeon-controlled patient cart that includes a 3D high-definition vision system and multi-articulating instruments for performing MIS procedures, and a surgeon workstation that provides an advanced ergonomic interface to the patient cart and a 3D endoscopic view inside the patient’s body. Titan intends to initially pursue focused surgical indications for the SPORT Surgical System, which may include one or more of gynecologic, urologic, colorectal or general abdominal procedures.

For more information, please visit the Company’s website at .

Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws. Such statements reflect the current expectations of management of the Company’s future growth, results of operations, performance and business prospects and opportunities. Wherever possible, words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions have been used to identify these forward-looking statements. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the “Risk Factors” section of the Company’s Annual Information Form dated March 31, 2018 (which may be viewed at ). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, the Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Contacts:

LHA Investor Relations

Kim Sutton Golodetz

(212) 838-3777



or

Bruce Voss

(310) 691-7100

EN
09/07/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Titan Medical

 PRESS RELEASE

Titan Medical to Issue Second Quarter 2022 Financial Results on August...

Titan Medical to Issue Second Quarter 2022 Financial Results on August 11, 2022 Webcast to Follow Announcement TORONTO, July 25, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on single access robotic-assisted surgery (RAS), today announced that the company plans to issue its second quarter 2022 financial results prior to market opening on Thursday, August 11, 2022. In addition, management will host an investor audio webcast at 8:30 a.m. ET to discuss financial results and business developments in the period. Speakers will incl...

 PRESS RELEASE

Titan Medical Announces Appointment of Cary G. Vance as President and ...

Titan Medical Announces Appointment of Cary G. Vance as President and Chief Executive Officer TORONTO, June 30, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced that Cary G. Vance has been appointed as the company’s President and CEO effective July 1, 2022. Mr. Vance will succeed Paul Cataford, Titan’s chair of the board of directors, who has served as Interim President and CEO since December 20...

 PRESS RELEASE

Titan Medical Provides Update to Enos Project Timeline

Titan Medical Provides Update to Enos Project Timeline De Novo marketing authorization planned for early 2025 remains unchanged TORONTO, June 28, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced that multiple disruptions have resulted in an updated Investigational Device Exemption (IDE) submission timeline for the Enos™ robotic single access surgery system. The company now expects the IDE subm...

 PRESS RELEASE

Titan Medical Announces Agreement with Nissha Medical Technologies

Titan Medical Announces Agreement with Nissha Medical Technologies TORONTO, ON, June 21, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced that it has signed an agreement with Nissha Medical Technologies for the manufacture of surgical consumables. These single-use surgical components will be used for verification and validation testing, and pre-clinical and clinical studies of Titan’s Enos™ robo...

 PRESS RELEASE

Titan Medical Achieves all Third Quarter Milestones Related to the Dev...

Titan Medical Achieves all Third Quarter Milestones Related to the Development of the SPORT Surgical System TORONTO, Oct. 04, 2018 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in single-port minimally invasive surgery (“MIS”), announces that the Company has achieved all of its publicly stated third quarter 2018 development milestones for the SPORT Surgical System, as follows: Completed the improved camera insertio...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch